Figure 3.

Network diagram describing how the components of the malaria model are organized into modules. Modularity ensures that specialists in a particular field, such as antimalarial drug pharmacokinetics or malaria infection and immunity, can add detail or develop new modules in their area of specialty while reducing the risk of inadvertently changing other components of the model. Even with modularity, software testing is required to formally show that a change was isolated to one feature of the model and did not inadvertently change other features. Similarly, it is necessary to check that a change to the common framework made by one disease specialist did not cause undesirable changes for other diseases supported by the common framework. For this reason, EMOD comes with (as of March 2018) over 600 regression tests and over 140 SFTs. The tests are run daily with the latest build of the EMOD codebase to automatically flag which model components have been modified.